Εμφανίζονται 1 - 17 Αποτελέσματα από 17 για την αναζήτηση '"деменция с тельцами леви"', χρόνος αναζήτησης: 0,59δλ Περιορισμός αποτελεσμάτων
  1. 1
    Academic Journal

    Πηγή: Acta Biomedica Scientifica; Том 8, № 6 (2023); 153-161 ; 2587-9596 ; 2541-9420

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.actabiomedica.ru/jour/article/view/4501/2689; Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021; 27(6): 954-963. doi:10.1038/s41591-021-01382-x; GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019; 18(1): 88-106. doi:10.1016/S1474-4422(18)30403-4; Trist BG, Hare DJ, Double KL. A proposed mechanism for neurodegeneration in movement disorders characterized by metal dyshomeostasis and oxidative stress. Cell Chem Biol. 2018; 25(7): 807-816. doi:10.1016/j.chembiol.2018.05.004; Vaikath NN, Erskine D, Morris CM, Majbour NK, Vekrellis K, Li JY, et al. Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer’s disease. Neuropathol Appl Neurobiol. 2019; 45(6): 597-608. doi:10.1111/nan.12531; Pineda A, Burre J. Modulating membrane binding of alphasynuclein as a therapeutic strategy. Proc Natl Acad Sci U S A. 2017; 114: 1223-1225. doi:10.1073/pnas.1620159114; Peng C, Gathagan RG, Lee VM-Y. Distinct α-synuclein strains and implications for heterogeneity among α-synucleinopathies. Neurobiol Dis. 2018; 109: 209-218. doi:10.1016/j.nbd.2017.07.018; Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm. 2004; 111(10-11): 1219-1235. doi:10.1007/s00702-004-0138-7; Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson’s disease. Mov Disord. 2013; 28(6): 811-813. doi:10.1002/mds.25421; Burre J, Sharma M, Südhof TC. Cell biology and pathophysiology of a-synuclein. Cold Spring Harb Perspect Med. 2018; 8: a024091. doi:10.1101/cshperspect.a024091; Allison JR, Rivers RC, Christodoulou JC, Vendruscolo M, Dobson CM. A relationship between the transient structure in the monomeric state and the aggregation propensities of α-synuclein and β-synuclein. Biochemistry. 2014; 53(46): 7170-7183. doi:10.1021/bi5009326; Breydo L, Wu JW, Uversky VN. Α-synuclein misfolding and Parkinson’s disease. Biochim Biophys Acta. 2012; 1822(2): 261-285. doi:10.1016/j.bbadis.2011.10.002; Goedert M, Masuda-Suzukake M, Falcon B. Like prions: The propagation of aggregated tau and α-synuclein in neurodegeneration. Brain. 2017; 140(2): 266-278. doi:10.1093/brain/aww230; Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E. Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol. 2010; 6(12): 702-706. doi:10.1038/nrneurol.2010.145; Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, et al. Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell. 2013; 154(1): 103-117. doi:10.1016/j.cell.2013.05.057; Irwin DJ, Lee VM, Trojanowski JQ. Parkinson’s disease dementia: Convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci. 2013; 14(9): 626-636. doi:10.1038/nrn3549; Ayers JI, Lee J, Monteiro O, Woerman AL, Lazar AA, Condello C, et al. Different α-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy. Proc Natl Acad Sci U S A. 2022; 119(6): e2113489119. doi:10.1073/pnas.2113489119; Bartels T, Choi JG, Selkoe DJ. α-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011; 477(7362): 107-110. doi:10.1038/nature10324; Wang W, Perovic I, Chittuluru J, Kaganovich A, Nguyen LT, Liao J, et al. A soluble α-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A. 2011; 108(43): 17797-17802. doi:10.1073/pnas.1113260108; Middleton ER, Rhoades E. Effects of curvature and composition on α-synuclein binding to lipid vesicles. Biophys J. 2010; 99(7): 2279-2288. doi:10.1016/j.bpj.2010.07.056; Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE. Alpha-synuclein membrane interactions and lipid specificity. J Biol Chem. 2000; 275(44): 34328-34334. doi:10.1074/jbc.M004345200; Jao CC, Hegde BG, Chen J, Haworth IS, Langen R. Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement. Proc Natl Acad Sci U S A. 2008; 105(50): 19666-19671. doi:10.1073/pnas.0807826105; Trexler AJ, Rhoades E. Alpha-synuclein binds large unilamellar vesicles as an extended helix. Biochemistry. 2009; 48(11): 2304-2306. doi:10.1021/bi900114z; Yonetani M, Nonaka T, Masuda M, Inukai Y, Oikawa T, Hisanaga S, et al. Conversion of wild-type alpha-synuclein into mutanttype fibrils and its propagation in the presence of A30P mutant. J Biol Chem. 2009; 284(12): 7940-7950. doi:10.1074/jbc.M807482200; Guiney SJ, Adlard PA, Lei P, Mawal CH, Bush AI, Finkelstein DI, et al. Fibrillar a-synuclein toxicity depends on functional lysosomes. J Biol Chem. 2020; 295(51): 17497-17513. doi:10.1074/jbc.RA120.013428; Bourdenx M, Nioche A, Dovero S, Arotcarena ML, Camus S, Porras G, et al. Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates. Sci Adv. 2020; 6(20): eaaz9165. doi:10.1126/sciadv.aaz9165; Pranke IM, Morello V, Bigay J, Gibson K, Verbavatz JM, Antonny B, et al. α-synuclein and ALPS motifs are membrane curvature sensors whose contrasting chemistry mediates selective vesicle binding. J Cell Biol. 2011; 194(1): 89-103. doi:10.1083/jcb.201011118; Hatzakis NS, Bhatia VK, Larsen J, Madsen KL, Bolinger PY, Kunding AH, et al. How curved membranes recruit amphipathic helices and protein anchoring motifs. Nat Chem Biol. 2009; 5(11): 835-841. doi:10.1038/nchembio.213; Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM, Egami K, et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alphasynuclein. J Biol Chem. 2011; 286(23): 20710-20726. doi:10.1074/jbc.M110.213538; Chinta SJ, Mallajosyula JK, Rane A, Andersen JK. Mitochondrial α-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett. 2010; 486(3): 235-239. doi:10.1016/j.neulet.2010.09.061; Volles MJ, Lansbury PT Jr. Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol. 2007; 366(5): 1510-1522. doi:10.1016/j.jmb.2006.12.044; Adamczyk A, Strosznajder JB. Alpha-synuclein potentiates Ca2+ influx through voltage-dependent Ca2+ channels. Neuroreport. 2006; 17(18): 188-1886. doi:10.1097/WNR.0b013e3280115185; Dettmer U, Newman AJ, Luth ES, Bartels T, Selkoe D. In vivo cross-linking reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-neural cells. J Biol Chem. 2013; 288(9): 6371-6385. doi:10.1074/jbc.M112.403311; Olanow CW, Brundin P. Parkinson’s disease and alpha synuclein: Is Parkinson’s disease a prion-like disorder? Mov Disord. 2013; 28(1): 31-40. doi:10.1002/mds.25373; Wilkaniec A, Strosznajder JB, Adamczyk A. Toxicity of extracellular secreted alpha-synuclein: Its role in nitrosative stress and neurodegeneration. Neurochem Int. 2013; 62(5): 776-783. doi:10.1016/j.neuint.2013.02.004; Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000; 287(5456): 1265-1269. doi:10.1126/science.287.5456.1265; Tabner BJ, Turnbull S, El-Agnaf OM, Allsop D. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease. Free Radic Biol Med. 2002; 32(11): 1076-1083. doi:10.1016/s0891-5849(02)00801-8; Nakamura T, Lipton SA. According to GOSPEL: Filling in the GAP(DH) of NO-mediated neurotoxicity. Neuron. 2009; 63(1): 3-6. doi:10.1016/j.neuron.2009.06.013; Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000; 290(5493): 985-989. doi:10.1126/science.290.5493.985; Bendor JT, Logan TP, Edwards RH. The function of asynuclein. Neuron. 2013; 79(6): 1044-1066. doi:10.1016/j.neuron.2013.09.004; Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain. 2013; 136(8): 2419-2431. doi:10.1093/brain/awt192; Annerino DM, Arshad S, Taylor GM, Adler CH, Beach TG, Greene JG. Parkinson’s disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol. 2012; 124(5): 665-680. doi:10.1007/s00401-012-1040-2; Matsuoka Y, Vila M, Lincoln S, McCormack A, Picciano M, LaFrancois J, et al. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis. 2001; 8(3): 535-539. doi:10.1006/nbdi.2001.0392; Markesbery WR, Jicha GA, Liu H, Schmitt FA. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol. 2009; 68(7): 816-822. doi:10.1097/NEN.0b013e3181ac10a7; Иллариошкин С.Н., Власенко А.Г., Федотова Е.Ю. Современные возможности идентификации латентной стадии нейродегенеративного процесса. Анналы клинической и экспериментальной неврологии. 2013; 7(2): 39-50.; Худоерков Р.М., Воронков Д.Н., Богданов Р.Р., Соболев В.Б., Борисова С.Ю., Давыдов И.А., и др. Исследование α-синуклеина в биоптатах подъязычных слюнных желез при болезни Паркинсона. Неврологический журнал. 2016; 21(3): 152-157. doi:10.18821/1560-9545-2016-21-3-152-157; Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003; 24(2): 197-211. doi:10.1016/s0197-4580(02)00065-9; Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: A dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007; 33(6): 599-614. doi:10.1111/j.1365-2990.2007.00874.x; Halliday G, McCann H, Shepherd C. Evaluation of the Braak hypothesis: How far can it explain the pathogenesis of Parkinson’s disease? Expert Rev Neurother. 2012; 12(6): 673-686. doi:10.1586/ern.12.47; El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, et al. Detection of oligomeric forms of alphasynuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J. 2006; 20(3): 419-425. doi:10.1096/fj.03-1449com; Braak H, Del Tredici K. Neuropathological staging of brain pathology in sporadic Parkinson’s disease: Separating the wheat from the chaff. J Parkinsons Dis. 2017; 7(1): 71-85. doi:10.3233/JPD-179001; Orimo S, Uchihara T, Nakamura A, Mori F, Ikeuchi T, Onodera O, et al. Cardiac sympathetic denervation in Parkinson’s disease linked to SNCA duplication. Acta Neuropathol. 2008; 116(5): 575-577. doi:10.1007/s00401-008-0428-5; Eggers C, Kahraman D, Fink GR, Schmidt M, Timmermann L. Akinetic-rigid and tremor-dominant Parkinson’s disease patients show different patterns of FP-CIT single photon emission computed tomography. Mov Disord. 2011; 26(3): 416-423. doi:10.1002/mds.23468; Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proc Natl Acad Sci U S A. 2002; 99(16): 10813-10818. doi:10.1073/pnas.152339799; Zhang W, Dallas S, Zhang D, Guo JP, Pang H, Wilson B, et al. Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alphasynuclein. Glia. 2007; 55(11): 1178-1188. doi:10.1002/glia.20532; Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: A process leading to disease progression in Parkinson’s disease. FASEB J. 2005; 19(6): 533-542. doi:10.1096/fj.04-2751com; Катунина Ю.А., Бездольный Ю.Н. Эпидемиология болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013; 113(12): 81-88.; Walker L, Stefanis L, Attems J. Clinical and neuropathological differences between Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies – Current issues and future directions. J Neurochem. 2019; 150(5): 467-474. doi:10.1111/jnc.14698; McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89(1): 88-100. doi:10.1212/WNL.0000000000004058; Jellinger KA. Dementia with Lewy bodies and Parkinson’s disease-dementia: Current concepts and controversies. J Neural Transm. 2018; 125: 615-650. doi:10.1007/s00702-017-1821-9; Kovari E, Horvath J, Bouras C. Neuropathology of Lewy body disorders. Brain Res Bull. 2009; 80: 203-210. doi:10.1016/j.brainresbull.2009.06.018; Tsuboi Y, Dickson DW. Dementia with Lewy bodies and Parkinson’s disease with dementia: Are they different? Parkinsonism Relat Disord. 2005; 11(1): 47-51. doi:10.1016/j.parkreldis.2004.10.014; Dickson DW. Parkinson’s disease and parkinsonism: Neuropathology. Cold Spring Harb Perspect Med. 2012; 2(8): a009258. doi:10.1101/cshperspect.a009258; Lantos PL. The definition of multiple system atrophy: A review of recent developments. J Neuropathol Exp Neurol. 1998; 57(12): 1099-1111. doi:10.1097/00005072-199812000-00001; Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain. 1994; 117: 235-243. doi:10.1093/brain/117.2.235; Wenning G, Tison F, Ben Shlomo Y, Daniel S, Quinn N. Multiple system atrophy: A review of 203 pathologically proven cases. Mov Disord. 1997; 12: 133-147. doi:10.1002/mds.870120203; Kim WS, Kågedal K, Halliday GM. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther. 2014; 6(5): 73. doi:10.1186/s13195-014-0073-2; Lee HJ, Suk JE, Bae EJ, Lee SJ. Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res Commun. 2008; 372: 423-428. doi:10.1016/j.bbrc.2008.05.045; Ruf WP, Meirelles JL, Danzer KM. Spreading of alphasynuclein between different cell types. Behav Brain Res. 2023; 436: 114059. doi:10.1016/j.bbr.2022.114059; Postina R. A closer look at alpha-secretase. Curr Alzheimer Res. 2008; 5(2): 179-186. doi:10.2174/156720508783954668; Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. Antibodies to alpha-synuclein detect Lewy bodies in many Down’s syndrome brains with Alzheimer’s disease. Ann Neurol. 1999; 45(3): 353-357. doi:10.1002/1531-8249(199903)45:33.0.co;2-4; Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A, et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun. 2013; 1: 65. doi:10.1186/2051-5960-1-65; Iseki E. Dementia with Lewy bodies: Reclassification of pathological subtypes and boundary with Parkinson’s disease or Alzheimer’s disease. Neuropathology. 2004; 24(1): 72-78. doi:10.1111/j.1440-1789.2003.00530.x; Shim KH, Kang MJ, Youn YC, An SSA, Kim S. Alpha-synuclein: A pathological factor with Aβ and tau and biomarker in Alzheimer’s disease. Alzheimers Res Ther. 2022; 14(1): 201. doi:10.1186/s13195-022-01150-0; Bassil F, Meymand ES, Brown HJ, Xu H, Cox TO, Pattabhiraman S, et al. α-synuclein modulates tau spreading in mouse brains. J Exp Med. 2021; 218(1): e20192193. doi:10.1084/jem.20192193; https://www.actabiomedica.ru/jour/article/view/4501

  2. 2
    Academic Journal
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
    Academic Journal

    Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 3, No 1 (2011); 46-51 ; Неврология, нейропсихиатрия, психосоматика; Vol 3, No 1 (2011); 46-51 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2011-1

    Περιγραφή αρχείου: application/pdf

    Relation: https://nnp.ima-press.net/nnp/article/view/73/76; Дамулин И.В., Яхно Н.Н. Дегенеративные заболевания с когнитивными расстройствами. В кн.: Болезни нервной системы. Рук-во для врачей. Под ред. Н.Н. Яхно. Т.1. М.: Медицина, 2007;192-245. Струценко А.А. Двигательные и вегетативные нарушения при деменции с тельцами Леви и болезни Паркинсона. Дис. … канд. мед. наук. М., 2004;138 с. Яхно Н.Н., Захаров В.В., Локшина А.Б. и др. Деменции. Рук-во для врачей. М.: Медпресс-информ, 2010;264 с. Thaisetthawatkul P. , Boeve B.F., Bennarroch E.E. et al. Autonomic dysfunction in dementia with Lewy bodies. Neurol 2004;62(10):1804-9. Ballard C., Shaw F. , McKeith I. et al. High prevalence of neurovascular instability in neurodegenerative dementias. Neurol 1998;51:1760-2. Okada Y., Ito Y., Aida J. et al. Lewy bodies in the sinoatrial nodal ganglion: Clinicopathological studies. Pathol Int 2004;54(9):682-7. Kashihara K., Ohno M., Kawada S. et al. Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies. J Nucl Med 2006;47(7):1099-101. Nakajima K., Yoshita M., Matsuo S. Iodine-123-MIBG sympathetic imaging in Lewy-body disease and related movement disorders. Q J Nucl Med Mol Imaging 2008;52(4):378-87. Преображенская И.С. Деменция с тельцами Леви. Дис. . докт. мед. наук. М., 2005;393 с. Преображенская И.С., Струценко А.А. Вегетативные расстройства при деменции с тельцами Леви. Журн неврол психиатр им. С.С. Корсакова 2005;105(2):24-8. Преображенская И.С., Яхно Н.Н., Захаров В.В. и др. Болезнь Альцгеймера и деменция с тельцами Леви: некоторые аспекты клиники, диагностики и лечения. РМЖ 2003;10(11):567-70. Захаров В.В., Локшина А.Б. Деменция с тельцами Леви: клиника, патологические проявления, лечение. Неврол журн 1998;5:57-62. Allan L., McKeith I., Ballard C. et al. The prevalence of autonomic symptoms in dementia and their association with physical activity, activities of daily living and quality of life. Dement Geriatr Cogn Disord 2006;22(3):230-7. Вейн А.М. Вегетативные расстройства: клиника, лечение, диагностика. Под ред. А.М. Вейна. М.: МИА, 2002;752 с. Hoehn N.H., Yahr M.D. Parkinsonism: onset, progression, and mortality. Neurol 1967;17:427-42. McKeith I.G., Galasko D., Kosaka K. et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurol 1996;47:1113-24. Fahn S., Elton R. UPDRS development committee. Unified Parkinson's disease rating scale. In: Fahn S., Marsden C., Calne D. (eds). Recent developments in Parkinson's disease. New York: Macmillan, 1987;153-63. Баевский Р.М., Кириллов О.И., Клецкин С.З. Математический анализ изменений сердечного ритма при стрессе. М.: Наука, 1984;221с. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. «Heart rate variability - Standards of Measurement, Physiological Interpretation, and Clinical Use», Special report. Eur Heart J 1996;17(3):354-81. Коршунов А.М. Особенности течения и эффективность лечения болезни Пар-кинсона. Дис. … докт. мед. наук. М., 2002;358 с. Allan L.M., Ballard C.G., Allen J. et al. Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatr 2007;78(7):761-7. Goldstein D.S., Holmes C.S., Dendi R. et al. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurol 2002;58(8):1247-55.

  10. 10
    Academic Journal

    Θεματικοί όροι: ВАРИАБЕЛЬНОСТЬ СЕРДЕЧНОГО РИТМА,ДЕМЕНЦИЯ С ТЕЛЬЦАМИ ЛЕВИ,БОЛЕЗНЬ ПАРКИНСОНА,HEART RHYTHM VARIABILITY,LEVY BODY DEMENTIA,PARKINSON"S DISEASE

    Περιγραφή αρχείου: text/html

  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
    Electronic Resource

    Additional Titles: Хвороба Паркінсона й паркінсонічні синдроми (лекція)
    Parkinson’s Disease and Parkinsonian Syndromes (Lecture)

    Πηγή: INTERNATIONAL NEUROLOGICAL JOURNAL; № 4.66 (2014); 16-31; МЕЖДУНАРОДНЫЙ НЕВРОЛОГИЧЕСКИЙ ЖУРНАЛ; МІЖНАРОДНИЙ НЕВРОЛОГІЧНИЙ ЖУРНАЛ; 2307-1419; 2224-0713